Related Experiment Videos
Hypocalcemia and parathyroid function in metastatic prostate cancer
Prabhat K Tandon1, Ali A Rizvi
1Division of Endocrinology, Diabetes, and Metabolism, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Summary
Hypocalcemia, a calcium deficiency, can be a rare complication of advanced prostate cancer that has spread to the bones. This case highlights the importance of considering cancer as a cause of low calcium levels.
Area of Science:
- Oncology
- Endocrinology
- Nephrology
Background:
- Prostate cancer is a common malignancy in older men.
- Hypocalcemia can arise from various causes, including endocrine and renal dysfunction.
- Metastatic bone disease can affect calcium homeostasis.
Observation:
- An 82-year-old man with metastatic prostate cancer presented with severe hypocalcemia (serum calcium 5.4 mg/dL).
- The hypocalcemia correlated temporally with the diagnosis and treatment of prostate cancer.
- Laboratory findings included normal magnesium and phosphorus, normal parathyroid hormone, low vitamin D, and reduced urinary calcium excretion.
Findings:
- The patient's hypocalcemia was attributed to prostate cancer metastatic to bone.
- Reduced calcium excretion and low vitamin D levels contributed to the condition.
- Notably, parathyroid hormone levels were normal, distinguishing it from typical secondary hyperparathyroidism.
Implications:
- This case underscores that hypocalcemia can be an unrecognized manifestation of prostate cancer.
- It suggests a possible functional hypoparathyroid state in the context of bone metastases.
- Clinicians should consider advanced prostate cancer in the differential diagnosis of unexplained hypocalcemia.